×
About 119,868 results

Ferroptosis inhibitor regulates the disease progression of systematic lupus erythematos...
https://doi.org/10.2174/1566524022666220525144630
Current Molecular Medicine; Yang B, Hou S et. al.

May 28th, 2022 - Systematic lupus erythematosus (SLE) is an autoimmune-mediated disease. So far, there is no relevant report on ferroptosis in SLE research, and the role of T helper 1 (Th1) and T helper 2 (Th2) cells in SLE is still unclear. This study employed SLE mice models with and without ferroptosis inhibitors(Liproxstatin‑1) and normal control mice. Treated mice were zanalyzed with hematoxylin and eosin ...

Comparative miRNA transcriptomics of macaques and mice reveals MYOC is an inhibitor for...
https://doi.org/10.1080/22221751.2022.2081619
Emerging Microbes & Infections; Li H, Han X et. al.

May 28th, 2022 - Cryptococcal meningoencephalitis (CM) is emerging as an infection in HIV/AIDS patients shifted from primarily ART- naive to ART-experienced individuals, as well as patients with COVID-19 and immunocompetent hosts. This fungal infection is mainly caused by the opportunistic human pathogen Cryptococcus neoformans. Brain or central nervous system (CNS) dissemination is the deadliest process for th...

Immune Checkpoint Inhibitors in Cancer Therapy.
https://doi.org/10.3390/curroncol29050247
Current Oncology (Toronto, Ont.); Shiravand Y, Khodadadi F et. al.

May 28th, 2022 - The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a significant breakthrough in the field of cancer immunotherapy. Therefore, humanized monoclonal antibodies, targeting these immune checkpoint proteins have been utilized successfully in patients with metastatic melanoma, renal cell carcinoma, head and neck cancers and non-small lung cancer. The US FDA has succ...

Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Can...
https://doi.org/10.3390/curroncol29050257
Current Oncology (Toronto, Ont.); Mulder K, Lim H et. al.

May 28th, 2022 - Gastric, esophageal and gastro-esophageal junction cancers are associated with inferior outcomes. For early-stage disease, perioperative chemotherapy or chemoradiation followed by surgery is the standard treatment. For most patients with advanced upper gastrointestinal tract cancers, platinum-based chemotherapy remains a standard treatment. Recently, several randomized clinical trials have demo...

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
https://clinicaltrials.gov/ct2/show/NCT04740307

May 27th, 2022 - The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis testing will be performed.

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT03816358

May 27th, 2022 - PRIMARY OBJECTIVE: I. To evaluate the safety and tolerability of anetumab ravtansine with the following combinations in patients with mesothelin positive pancreatic adenocarcinoma. SECONDARY OBJECTIVES: I. To assess the preliminary anti-tumor activity of anetumab ravtansine (anetumab) in combination with nivolumab, nivolumab and ipilimumab, nivolumab and gemcitabine hydrochloride (gemcitabine) ...

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

May 27th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but more common in the relapsed/refractory population due to its poor prognosis and response to standard purine analog chemotherapy. HCLv cells are CD25-neg...

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
https://clinicaltrials.gov/ct2/show/NCT04662086

May 27th, 2022 - The platform study allows investigational products with objectives either: evaluating viral shedding (Virology Domain); and COVID-19 related Clinical Outcomes (Clinical Domain). The primary objective for investigational products within the Viral Domain is: A. To evaluate the efficacy of each therapeutic intervention in addition to standard supportive care (SSC) compared with SSC in reducing vir...

COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
https://clinicaltrials.gov/ct2/show/NCT04662073

May 27th, 2022 - The platform study allows investigational products with objectives either: evaluating viral shedding (Virology Domain); and COVID-19 related Clinical Outcomes (Clinical Domain). The primary objective for investigational products within the Viral Domain is: A. To evaluate the efficacy of each therapeutic intervention in addition to standard supportive care (SSC) compared with SSC in reducing vir...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

May 27th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-haploidentical HCT When clinically translated, the dose (50 mg/kg) and timing (days +3 and +4) of PTCy used were partly extrapolated from murine major his...

Pomalidomide for Kaposi Sarcoma in People With or Without HIV
https://clinicaltrials.gov/ct2/show/NCT01495598

May 27th, 2022 - Background: Kaposi Sarcoma (KS) is an incurable, multicentric angioproliferative tumor that most frequently involves the skin. It is seen most frequently in people with HIV or other forms of immune compromise. Current therapies are limited by toxicities, including cumulative cardiotoxicity, while effective oral agents, agents deliverable in resource-limited settings, and agents deliverable long...

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT04739813

May 27th, 2022 - Background: Combination chemotherapy with rituximab has been the mainstay of treatment for CD20-positive B-cell lymphomas. Significant advances have been made in curing aggressive B-cell lymphomas with chemoimmunotherapy, but indolent lymphomas and relapsed/refractory aggressive lymphomas remain mostly incurable with chemotherapy alone. Targeted therapies, aimed at disrupting key survival pathw...

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
https://clinicaltrials.gov/ct2/show/NCT03970447

May 27th, 2022 - Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. Its goals are to identify effective therapies for glioblastoma and match effective therapies with patient subtypes. Bayesian response adaptive ...

'It's an Amazing Time to Be a Hemophilia Provider'
https://www.medscape.com/viewarticle/974738

May 27th, 2022 - New medications such as emicizumab (Hemlibra) are transforming the lives of patients with hemophilia A, and more treatments are in the pipeline. "It's an amazing time to be a hemophilia provider," Alice D. Ma, MD, University of North Carolina at Chapel Hill hematologist and bleeding disorder specialist, said in an interview. "There are real options, and it's very exciting." But the drugs come w...

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
https://clinicaltrials.gov/ct2/show/NCT00977977

May 27th, 2022 - This is a pilot intervention study to evaluate preliminary evidence of the safety and effectiveness of a novel combination immunosuppressive regimen, Rituximab plus cyclosporine, in the treatment of idiopathic membranous nephropathy. Membranous nephropathy is a condition that affects the kidney and involves damage to the walls of tiny blood vessels filters in the kidneys called glomeruli. This ...

Chronic Myelogenous Leukemia (CML) Medication
http://emedicine.medscape.com/article/199425-medication

May 27th, 2022 - Medication Summary The medications used for patients with chronic-phase chronic myelogenous leukemia (CML) aim at delaying the onset of the accelerated or blastic phase. This has traditionally included a myelosuppressive agent to achieve hematologic remission, but more effective drugs—successively, interferon alfa, then targeted therapy with tyrosine kinase inhibitors such as imatinib mesylate—...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

May 27th, 2022 - Background Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which have been developed by the Laboratory of Molecular Biology (LMB). HCL variants often resemble classic HCL but are more aggressive and less responsive to treatments, such as HCLv and IGHV4-34+ HCL that are im...

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
https://clinicaltrials.gov/ct2/show/NCT04566133

May 27th, 2022 - Background: Among the new cases of bile tract carcinoma (BTC) that are diagnosed every year in the United States, there are approximately 6,500 cases of gallbladder carcinoma, 3,000 cases of extrahepatic cholangiocarcinoma, and 3,000 cases of intrahepatic cholangiocarcinoma. Current treatment options for patients with cholangiocarcinoma are limited and take no account of the known biological an...

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02829723

May 27th, 2022 - The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors. Dose escalation...

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
https://clinicaltrials.gov/ct2/show/NCT04538378

May 27th, 2022 - Background: Targeted therapies designed for specific genetic alterations, known as cancer driver mutations, have changed the treatment paradigm in advanced non-small cell lung carcinoma (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in NSCLC with activating mutation in the EGFR. Although most patients achieve robust responses to EGFR TKIs with t...